Biopharmaceutical company (NASDAQ-listed)
Appears in 3 stories · Last updated Nov 17, 2026
Received complete response letter for ivonescimab; awaiting HARMONi-3 results
Summit Therapeutics' shares fell 15% on Nov. 16. The drop followed the Food and Drug Administration's rejection of ivonescimab, a lung cancer drug that targets two proteins called PD-1 and VEGF and had drawn attention as a potential challenge to Merck's Keytruda. The agency issued a complete response letter, meaning the application cannot be approved in its current form.
Updated 48 minutes ago
US partner for ivonescimab commercialization outside China
Patients with advanced biliary tract cancer lived a median of 14.9 months on ivonescimab plus chemotherapy, versus 12.1 months on durvalumab (Imfinzi) plus chemo. That is a 25% lower risk of death in the Phase III HARMONi-GI1 trial, which Akeso presented at the ESMO 2026 Presidential Symposium in Madrid on October 25.
Updated Oct 27
Recipient of investment; licenses ivonescimab outside China
AstraZeneca closed its $2 billion Summit Therapeutics investment on October 5: a straight equity purchase with no royalties or milestones attached, according to Biotech Morning. The cash funds trials pairing Summit's ivonescimab, a bispecific antibody that blocks PD-1 and VEGF, with AstraZeneca's antibody-drug conjugates.
Updated Oct 21
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?